CLYM

Climb Bio Inc

10.29

Nov 06 • 3:59 PM ET +1.42 (16.01%)

10.34

Aftermarket • 5:00 PM ET +0.05 (0.49%)

Healthcare Biotechnology USA Small NASD

Today, 12:15 PMWedbush raises Climb Bio price target to $27 from $25, reiterates Outperform and Best Ideas List status after Q3 results and updated clinical catalyst expectations

Peers: VERA JBIO TVTX ZBIO DNTH AUPH KYTX OMER ANAB CABA

| Held by: VTI XBI IWM VXF VTWO VFMO SCHA IWN DFAS FFSM

Scroll to Statements

Index	RUT
Market Cap	591.02M
Enterprise Value	386.67M
Income	-59.31M
Sales	0.00M
Book/sh	3.95
Cash/sh	3.58
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	28
IPO	Aug 10, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.60
P/C	2.88
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	26.58
Current Ratio	26.58
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.82
EPS next Y	-0.96
EPS next Q	-0.20
EPS this Y	12.61%
EPS next Y	-24.45%
EPS next 5Y	-15.04%
EPS past 3/5Y	19.93% -0.24%
Sales past 3/5Y	- -
EPS Y/Y TTM	-9.27%
Sales Y/Y TTM	-
EPS Q/Q	3.91%
Sales Q/Q	-
Earnings	Nov 05 BMO
EPS/Sales Surpr.	10.27% -

Insider Own	9.78%
Insider Trans	-2.28%
Inst Own	102.90%
Inst Trans	67.25%
ROA	-28.32%
ROE	-29.28%
ROIC	-25.94%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	2.21%
SMA50	-13.59%
SMA200	-2.12%
Trades

Shs Outstand	57.73M
Shs Float	51.82M
Short Float	18.89%
Short Ratio	6.94
Short Interest	9.79M
52W High	18.33 -43.86%
52W Low	1.63 529.36%
Volatility	7.26% 7.98%
ATR (14)	0.86
RSI (14)	48.21
Beta	0.05
Rel Volume	0.81
Avg Volume	1.41M
Volume	1,139,879

Perf Week	0.39%
Perf Month	-5.25%
Perf Quarter	-24.00%
Perf Half Y	-9.50%
Perf YTD	157.25%
Perf Year	427.69%
Perf 3Y	301.95%
Perf 5Y	-42.06%
Perf 10Y	-
Recom	1.06
Target Price	27.62
Prev Close	8.87
Price	10.29
Change %	16.01%

Consensus

Strong Buy

Avg. Price Target

$27.62

Implied Upside

+168.4%

Analysts16incl. previous ratings

Rating Distribution16 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 20, 2026	Initiated	DDeutsche Bank	Buy	$28	+172.1%
Aug 03, 2026	Initiated	RRBC Capital Mkts	Outperform	$23	+123.5%
Jun 08, 2026	Initiated	GGuggenheim	Buy	$35	+240.1%
May 05, 2026	Initiated	CChardan Capital Markets	Buy	$22	+113.8%
Apr 15, 2026	Initiated	MMizuho	Outperform	$18	+74.9%
Mar 24, 2026	Initiated	RB. Riley Securities	Buy	$26	+152.7%
Mar 18, 2026	Initiated	TTruist	Buy	$17	+65.2%
Mar 11, 2026	Initiated	RRaymond James	Strong Buy	$25	+143.0%
Mar 05, 2026	Initiated	WWedbush	Outperform	$12	+16.6%
Feb 13, 2026	Initiated	PPiper Sandler	Overweight	$23	+123.5%
Oct 16, 2025	Initiated	WWilliam Blair	Outperform
Oct 13, 2025	Initiated	HH.C. Wainwright	Buy	$9	-12.5%
Aug 15, 2025	Initiated	RRobert W. Baird	Outperform	$9	-12.5%
Jun 06, 2025	Initiated	OOppenheimer	Outperform	$10	-2.8%
May 22, 2025	Initiated	BBTIG Research	Buy	$7	-32.0%
Dec 02, 2024	Initiated	LLeerink Partners	Outperform	$10	-2.8%

Today 11:58AM	Wedbush keeps Climb Bio on Best Ideas List, raises price target (Investing.com) +16.01%
Nov-05-26 07:00AM	Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-04-26 11:24AM	Wedbush Says This Stock Remains a Top Pick Despite Recent Volatility (Investing.com)
09:00AM	Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Nov-02-26 07:00AM	Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference (GlobeNewswire)
07:30PM	Loading…
Oct-24-26 07:30PM	Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026 (GlobeNewswire)
Oct-23-26 04:01PM	Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 (GlobeNewswire) -13.54%
Oct-20-26 11:14AM	Deutsche Bank starts Climb Bio at Buy, citing compelling autoimmune pipeline (Investing.com) +11.00%
Oct-02-26 09:30AM	Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug (GlobeNewswire)
Oct-01-26 04:26PM	Raymond James Updates Healthcare Top Picks for October (Investing.com)
Sep-04-26 05:00AM	Ionis rare neurology drug approved; Pfizer inks an ADC deal (BioPharma Dive) +6.37%
Sep-03-26 09:37AM	Climb Bio Shares Rise 17% After Phase 1 CLYM116 Trial Data (InvestorsHub)
09:26AM	Why Climb Bio, Up 1,300% Over 17 Months, Just Skidded (Investor's Business Daily)
07:00AM	Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy (GlobeNewswire)
Sep-02-26 07:00AM	Climb Bio to Present at Upcoming Investor Conferences (GlobeNewswire)
07:00AM	Loading…
Aug-06-26 07:00AM	Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire) +12.27%
Jun-11-26 07:00AM	Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026 (GlobeNewswire)
Jun-05-26 07:00AM	Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development (GlobeNewswire)
May-26-26 07:00AM	Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026 (GlobeNewswire)
May-14-26 07:00AM	Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress (GlobeNewswire)
May-12-26 07:00AM	Climb Bio to Present at Upcoming Investor Conferences (GlobeNewswire)
May-07-26 07:00AM	Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
May-05-26 07:00AM	Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts (GlobeNewswire) +18.16%
Apr-28-26 07:00AM	Climb Bio, Inc. Announces $110.0 Million Private Placement (GlobeNewswire)
Apr-08-26 07:00AM	Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026 (GlobeNewswire)
Apr-07-26 07:00AM	Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy (GlobeNewswire)
Mar-05-26 07:00AM	Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-26-26 02:11AM	Climb Bio Highlights 2025 Data Catalysts, CD19 and APRIL Programs at Oppenheimer Conference (MarketBeat)
Feb-13-26 03:07AM	Climb Bio Teases 5 Data Readouts in 2026, Highlights CD19 and APRIL Sweeper Programs at Summit (MarketBeat) +7.59%
Feb-05-26 07:00AM	Climb Bio to Present at Upcoming Investor Conferences (GlobeNewswire) -7.92%
07:00AM	Loading…
Jan-08-26 07:00AM	Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 (GlobeNewswire) +9.05%
Dec-31-25 11:13AM	H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio's (CLYM) Budoprutug Across Clinical Tracks (Insider Monkey)
Nov-25-25 07:00AM	Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 07:01AM	Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-03-25 07:00AM	Climb Bio to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-31-25 05:42AM	William Blair Initiates Coverage of Climb Bio (CLYM) with Outperform Rating on Autoimmune Drug Potential (Insider Monkey)
Oct-21-25 07:00AM	Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy (GlobeNewswire)
Oct-17-25 07:00AM	Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025 (GlobeNewswire)
Oct-01-25 07:00AM	Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer (GlobeNewswire)
Sep-29-25 07:00AM	Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN (GlobeNewswire) -6.57%
Sep-11-25 09:40AM	Is Climb Bio, Inc. (CLYM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-04-25 07:00AM	Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025 (GlobeNewswire)
Sep-03-25 09:55AM	Climb Bio, Inc. (CLYM)'s Technical Outlook is Bright After Key Golden Cross (Zacks) +9.42%
Aug-25-25 02:41PM	UPDATE - Climb Bio to Present at Upcoming September 2025 Investor Conferences (GlobeNewswire)
07:00AM	Climb Bio to Present at Upcoming September 2025 Investor Conferences (GlobeNewswire)
Aug-20-25 09:40AM	Is Climb Bio, Inc. (CLYM) Outperforming Other Medical Stocks This Year? (Zacks) +11.39%
Aug-12-25 07:00AM	Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-03-25 06:25AM	Oppenheimer Predicts Up to 590% Rally for These 2 Strong Buy Stocks (TipRanks)
Jun-18-25 07:00AM	Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer (GlobeNewswire)
May-19-25 04:34PM	Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-14-25 07:00AM	Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -7.87%
May-08-25 05:40PM	Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX, ACB (PR Newswire)
Apr-10-25 01:08PM	Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX (Exec Edge)
Apr-01-25 07:00AM	Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
Mar-27-25 07:00AM	Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-25 04:38PM	Climb Bio Fueled Up with Cash, Poised for More Milestones in 25 Quarterly Update Report (Exec Edge)
Mar-25-25 04:05PM	Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-20-25 02:07PM	Climb Bio: Meet The Newest Star in Autoimmune Disease Treatment Initiation Report (Exec Edge) -5.19%
Feb-25-25 07:00AM	Climb Bio to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-24-25 07:00AM	Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer (GlobeNewswire)
Feb-04-25 07:00AM	Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire) -6.03%
Jan-09-25 07:00AM	Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy (GlobeNewswire)
Dec-19-24 07:00AM	Climb Bio to be Added to the Nasdaq Biotechnology Index (GlobeNewswire)
Nov-12-24 04:05PM	Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) -6.40% -7.11%
Nov-11-24 07:00AM	Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board (GlobeNewswire) +7.12%
Oct-31-24 07:00AM	Climb Bio to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-15-24 07:00AM	Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event (GlobeNewswire) -6.25%
Oct-11-24 12:30PM	Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024 (GlobeNewswire) +5.45%
Oct-04-24 07:00AM	Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19 (GlobeNewswire)
Oct-03-24 10:00AM	Climb Bio to Host Virtual Investor Event on October 15, 2024 (GlobeNewswire)
Oct-02-24 07:04PM	Eliem Therapeutics Changes Name to Climb Bio (Exec Edge)
09:00AM	Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc. (GlobeNewswire)
Sep-11-24 07:00AM	Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit (GlobeNewswire)
Aug-26-24 07:00AM	Eliem Therapeutics Announces Additions to its Leadership Team (GlobeNewswire)
Aug-14-24 06:05AM	Eliem Therapeutics Reports Second Quarter Financial Results (GlobeNewswire)
Jul-24-24 12:11AM	Insider Sale at Eliem Therapeutics Inc: EVP, R&D AND CSO Valerie Morisset Sells Shares (GuruFocus.com)
Jul-19-24 03:00PM	Insider Sale at Eliem Therapeutics Inc (ELYM): EVP, R&D AND CSO Valerie Morisset Sells ... (GuruFocus.com) +7.83%
Jul-18-24 01:01AM	EVP, R&D AND CSO Valerie Morisset Sells 50,000 Shares of Eliem Therapeutics Inc (ELYM) (GuruFocus.com)
Jul-17-24 12:42AM	Insider Sale at Eliem Therapeutics Inc (ELYM): EVP, R&D AND CSO Valerie Morisset Sells ... (GuruFocus.com)
Jul-12-24 01:46AM	Insider Sale at Eliem Therapeutics Inc: EVP, R&D AND CSO Valerie Morisset Sells 105,931 Shares (GuruFocus.com)
Jun-28-24 07:00AM	Eliem Therapeutics Announces its Addition to the Russell 2000 and Russell 3000 Indexes (GlobeNewswire) -5.58%
Jun-27-24 04:01PM	Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement (GlobeNewswire)
May-15-24 01:53PM	ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q1 2024 (InvestorPlace)
Apr-11-24 02:42PM	Eliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines Deal (Benzinga) +71.54%
07:00AM	Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement (GlobeNewswire)
Apr-05-24 06:53AM	ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q4 2023 (InvestorPlace) -6.81%
Jul-21-23 07:17AM	Eliem (ELYM) to Explore Strategic Options, Stock Rises 6% (Zacks) -8.39%
Jul-20-23 06:45AM	Eliem Therapeutics Announces Plans to Explore Strategic Alternatives (GlobeNewswire) +6.43%
May-11-23 04:10PM	Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights (GlobeNewswire) -10.22%
Apr-21-23 12:00PM	We're Hopeful That Eliem Therapeutics (NASDAQ:ELYM) Will Use Its Cash Wisely (Simply Wall St.)
10:39AM	Top 10 Stocks Activist Investors Are Targeting (Insider Monkey)
Mar-06-23 04:10PM	Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights (GlobeNewswire)
Feb-23-23 12:38AM	Eliem Therapeutics slashing staff amid leadership shakeup (American City Business Journals) +24.35%
Feb-10-23 09:31AM	Eliem Pauses Development On Depression Drug, Lays Off 55% Workforce (Benzinga)
Feb-09-23 04:01PM	Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition (GlobeNewswire)
Nov-30-22 07:00AM	Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference (GlobeNewswire) -5.19%
Nov-14-22 06:10AM	Eliem Therapeutics Reports Third Quarter Financial and Business Highlights (GlobeNewswire)
Nov-12-22 08:47AM	Is Eliem Therapeutics (NASDAQ:ELYM) In A Good Position To Invest In Growth? (Simply Wall St.)
Nov-08-22 07:00AM	Eliem Therapeutics to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Oct-05-22 11:20AM	Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study (Benzinga)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director	Sep 28 '26	Option Exercise	2.79	70,000	195,100	70,000	Sep 30 04:55 PM
Thomas Stephen Basil	Director	Sep 15 '26	Sale	13.67	100,000	1,366,820	467,969	Sep 17 04:15 PM
STEPHEN THOMAS	Director	Sep 15 '26	Proposed Sale	14.56	100,000	1,456,000		Sep 15 04:27 PM
Brennan Aoife	President and CEO	Jun 29 '26	Sale	13.17	30,902	406,979	87,731	Jun 30 07:50 PM
AOIFE BRENNAN	Officer	Jun 29 '26	Proposed Sale	13.17	30,902	406,968		Jun 30 07:49 PM
Thomas Stephen Basil	Director	Feb 25 '26	Sale	7.00	33,687	235,964	170,970	Feb 27 04:05 PM
Thomas Stephen Basil	Director	Feb 26 '26	Sale	7.01	16,313	114,289	154,657	Feb 27 04:05 PM
STEPHEN THOMAS	Director	Feb 25 '26	Proposed Sale	6.36	50,000	318,000		Feb 25 04:26 PM
Thomas Stephen Basil	Director	Feb 12 '26	Sale	5.23	90,000	470,988	214,657	Feb 17 04:05 PM
Thomas Stephen Basil	Director	Feb 13 '26	Sale	5.81	10,000	58,141	204,657	Feb 17 04:05 PM
STEPHEN THOMAS	Director	Feb 12 '26	Proposed Sale	5.56	100,000	556,000		Feb 12 04:28 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jan 05 '26	Buy	3.50	7,111	24,888	3,403,429	Jan 07 04:55 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Dec 11 '25	Buy	2.18	213,099	464,556	3,294,856	Dec 15 07:55 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Dec 12 '25	Buy	2.86	101,462	290,181	3,396,318	Dec 15 07:55 PM

Climb Bio, Inc. operates as a clinical-stage biotechnology company. The firm develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.

BChDr. Aoife M. Brennan BAO

Ph.D.Dr. Susan Altschuller M.B.A.

Ph.D.Dr. Perrin Wilson B.S.

Senior Vice President of Technical OperationsMr. Adam Villa

Senior VPMs. Chandra Adams J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLYM

Climb Bio Inc

Upgrade your Finviz experience